An Anti-Cancer Drug Candidate CYC116 Suppresses Type I Hypersensitive Immune Responses through the Inhibition of Fyn Kinase in Mast Cells

Mast cells are the most prominent effector cells of Type 1 hypersensitivity immune responses. CYC116 [4-(2-amino-4-methyl-1,3-thiazol-5-yl)-N-[4-(morpholin-4-yl)phenyl] pyrimidin-2-amine] is under development to be used as an anti-cancer drug, but the inhibitory effects of CYC116 on the activation o...

Full description

Saved in:
Bibliographic Details
Published in:Biomol Ther (Seoul)
Main Authors: Park, Young Hwan, Kim, Hyun Woo, Kim, Hyuk Soon, Nam, Seung Taek, Lee, Dajeong, Lee, Min Bum, Min, Keun Young, Koo, Jimo, Kim, Su Jeong, Kim, Young Mi, Kim, Hyung Sik, Choi, Wahn Soo
Format: Artigo
Language:Inglês
Published: The Korean Society of Applied Pharmacology 2019
Subjects:
Original Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6513188/
https://ncbi.nlm.nih.gov/pubmed/30332888
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4062/biomolther.2018.148
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items